Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Posts 15 Percent Q2 Sales Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported that its second-quarter revenues increased 15 percent led by its fine chemicals business.

The St. Louis-based chemicals and research products firm generated total revenues of $637 million for the three months ended June 30, compared to $554 million for the second quarter of 2010. Excluding an 8 percent contribution from currency exchange and a 1 percent benefit from acquisitions, Sigma-Aldrich's organic revenues were up 6 percent. The firm beat analysts' consensus estimate of $621.2 million.

Sigma-Aldrich's Research Essentials business grew 16 percent year over year to $124 million; its Research Specialties business increased 14 percent to $236 million; and its Research Biotech business jumped 13 percent to $94 million. Sigma-Aldrich Fine Chemicals' sales increased 17 percent to $183 million.

The firm posted net income of $113 million, or $.91 per share, up from $97 million, or $.79 per share, for Q2 2010.

Its R&D spending increased 6 percent to $18 million from $17 million, and its SG&A spending was up 14 percent at $151 million from $132 million.

Sigma-Aldrich finished the quarter with $663 million in cash and cash equivalents.

The company said that it expects full-year 2011 organic revenues to increase in the mid-single digits. Currency translation is expected to add around 5 percent growth, while acquisitions are anticipated to add between 1 and 2 percent growth. The firm's outlook for EPS is unchanged at a range between $3.60 and $3.75.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.